Effient, Efient(prasugrel)
Effient, Efient (prasugrel) is a small molecule pharmaceutical. Prasugrel was first approved as Efient on 2009-02-24. It has been approved in Europe to treat acute coronary syndrome, myocardial infarction, and unstable angina.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Effient (generic drugs available since 2017-07-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prasugrel hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EFFIENT | Cosette Pharmaceuticals | N-022307 RX | 2009-07-10 | 2 products, RLD, RS |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
153 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | 2 | 6 | 8 | 28 | 4 | 48 | |
| Acute coronary syndrome | D054058 | EFO_0005672 | 1 | 5 | 14 | 25 | 3 | 46 | |
| St elevation myocardial infarction | D000072657 | — | 1 | 5 | 6 | 1 | 12 | ||
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | 8 | — | 10 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | — | 6 | — | 8 |
| Healthy volunteers/patients | — | 6 | — | — | 1 | — | 7 | ||
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 2 | 2 | — | 4 |
| Percutaneous coronary intervention | D062645 | — | 2 | 3 | 1 | — | 4 | ||
| Thrombosis | D013927 | — | — | 1 | 3 | — | 4 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | 2 | 1 | 4 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | 1 | — | — | 5 |
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 1 | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Aspirin-induced asthma | D055963 | HP_0012042 | — | 1 | — | — | — | 1 | |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 1 | 1 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Patent foramen ovale | D054092 | HP_0001655 | Q21.12 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PRASUGREL |
| INN | prasugrel |
| Description | 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate is a member of the class of thienopyridines that is 2-acetoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the amino hydrogen is replaced by a 2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl group. It is an acetate ester, a member of cyclopropanes, a ketone, a member of monofluorobenzenes, a tertiary amino compound and a thienopyridine. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2 |
Identifiers
| PDB | — |
| CAS-ID | 150322-43-3 |
| RxCUI | 613391 |
| ChEMBL ID | CHEMBL1201772 |
| ChEBI ID | 87723 |
| PubChem CID | 6918456 |
| DrugBank | DB06209 |
| UNII ID | 34K66TBT99 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Effient - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,267 documents
View more details
Safety
Black-box Warning
Black-box warning for: Effient, Prasugrel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,122 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more